JRS Pharma taps into Chinese market with cDMF filings for excipients portfolio

Ingredients by the German excipient maker have been included in the Chinese Drug Master File with the National Medical Products Administration

JRS Pharma, the German excipient manufacturer with a global footprint, has announced that many of its excipient products are being registered with the National Medical Products Administration (NMPA, former CFDA).

The NMPA is the Chinese agency tasked to draft laws and regulations for drugs and medical devices in China.

These cDMF filings allow global pharmaceutical companies to manufacture and sell pharmaceutical products in China, utilising many of JRS Pharma's excipients.

Compliant products include:

  • VIVAPUR (grades 105, 101, 102, 102SCG, 12, 200, & 112)
  • PROSOLV SMCC (grades 50, 90, & HD 90)
  • EMCOCEL (grades 50M, 90M, & 90M Course)
  • LUBRITAB
  • VIVASTAR P 
  • VIVASTAR P 1000SF
  • EXPLOTAB
  • PRUV
  • ELCEMA F 150
  • VIVASOL
  • VIVAPHARM PVP K30
  • VIVAPHARM PVP K25
  • VIVAPHARM PVPP
  • VIVAPHARM PVP VA

Featured Companies

JRS Pharma (more information, website)